AU1122099A - Enhancement of morphogen activity - Google Patents

Enhancement of morphogen activity Download PDF

Info

Publication number
AU1122099A
AU1122099A AU11220/99A AU1122099A AU1122099A AU 1122099 A AU1122099 A AU 1122099A AU 11220/99 A AU11220/99 A AU 11220/99A AU 1122099 A AU1122099 A AU 1122099A AU 1122099 A AU1122099 A AU 1122099A
Authority
AU
Australia
Prior art keywords
xaa
morphogen
res
receptor
molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU11220/99A
Other languages
English (en)
Inventor
Marc F. Charette
Dennis Higgins
David C. Rueger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Curis Inc
Original Assignee
Curis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curis Inc filed Critical Curis Inc
Publication of AU1122099A publication Critical patent/AU1122099A/en
Assigned to CURIS, INC. reassignment CURIS, INC. Alteration of Name(s) of Applicant(s) under S113 Assignors: CREATIVE BIOMOLECULES, INC.
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AU11220/99A 1997-10-27 1998-10-26 Enhancement of morphogen activity Abandoned AU1122099A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6362497P 1997-10-27 1997-10-27
US60063624 1997-10-27
PCT/US1998/022655 WO1999021574A2 (en) 1997-10-27 1998-10-26 Enhancement of morphogen activity

Publications (1)

Publication Number Publication Date
AU1122099A true AU1122099A (en) 1999-05-17

Family

ID=22050440

Family Applications (1)

Application Number Title Priority Date Filing Date
AU11220/99A Abandoned AU1122099A (en) 1997-10-27 1998-10-26 Enhancement of morphogen activity

Country Status (5)

Country Link
EP (1) EP1027059A2 (de)
JP (1) JP2002506000A (de)
AU (1) AU1122099A (de)
CA (1) CA2307826A1 (de)
WO (1) WO1999021574A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2363965C (en) 1991-03-11 2010-05-18 Curis, Inc. Protein-induced morphogenesis
GB9907461D0 (en) * 1999-03-31 1999-05-26 King S College London Neurite regeneration
US20030170213A1 (en) * 1998-01-23 2003-09-11 Marc F. Charette Methods and compositions for enhancing cognitive function using morphogenic proteins
CA2385887A1 (en) * 1999-09-27 2001-04-05 John C. Lee Compositions and therapeutic methods using morphogenic proteins, hormones and hormone receptors
US6696410B1 (en) 1999-09-27 2004-02-24 Stryker Corporation Compositions and therapeutic methods using morphogenic proteins, hormones and hormone receptors
DE60132436T2 (de) * 2000-03-30 2008-04-17 Oxford Biomedica (Uk) Ltd. Retinolsäure-rezeptor beta-2 und gentherapievektoren für die behandlung von neurologischen erkrankungen
JP2005500027A (ja) * 2001-06-11 2005-01-06 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ ドーパミン分泌細胞の生存を増加させる方法
AU2004212843B2 (en) * 2003-02-24 2009-06-25 Chugai Seiyaku Kabushiki Kaisha Remedy for spinal injury containing interleukin-6 antagonist
CA2554644C (en) 2004-02-02 2015-06-16 Pioneer Hi-Bred International, Inc. Ap2 domain transcription factor odp2 (ovule development protein 2) and methods of use
US8704041B2 (en) 2009-12-30 2014-04-22 Pioneer Hi Bred International Inc Methods and compositions for targeted polynucleotide modification
AU2010339404B2 (en) 2009-12-30 2016-01-28 Pioneer Hi-Bred International, Inc. Methods and compositions for the introduction and regulated expression of genes in plants

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6040431A (en) * 1995-06-07 2000-03-21 Stryker Corporation Single chain analogs of the TGF-β superfamily (morphons)
US5834188A (en) * 1995-07-26 1998-11-10 Creative Biomolecule, Inc. Methods and compositions for identifying morphogen analogs
EP0845006A2 (de) * 1995-08-14 1998-06-03 Creative Biomolecules, Inc. Bindung des osteogenen proteins-i (op-1) und dessen analoge an den zelloberflächenrezeptor alk-1 und dessen analoge

Also Published As

Publication number Publication date
CA2307826A1 (en) 1999-05-06
WO1999021574A2 (en) 1999-05-06
JP2002506000A (ja) 2002-02-26
EP1027059A2 (de) 2000-08-16
WO1999021574A3 (en) 1999-07-08
WO1999021574A9 (en) 1999-08-12

Similar Documents

Publication Publication Date Title
Meyer et al. Enhanced synthesis of brain-derived neurotrophic factor in the lesioned peripheral nerve: different mechanisms are responsible for the regulation of BDNF and NGF mRNA.
US6632618B1 (en) Morphogenic protein-specific cell surface receptors and uses therefor
Weise et al. Localization of bFGF and FGF‐receptor in the developing nervous system of the embryonic and newborn rat
Ai et al. Activin and bone morphogenetic proteins induce calcitonin gene-related peptide in embryonic sensory neurons in vitro
CA2363965C (en) Protein-induced morphogenesis
US6723698B2 (en) Methods and compositions for the treatment of motor neuron injury and neuropathy
JPH08503198A (ja) Ｏｐ−３誘導形態形成
Mitsiadis et al. Patterns of nerve growth factor (NGF), proNGF, and p75 NGF receptor expression in the rat incisor: comparison with expression in the molar
JP5346657B2 (ja) 組織形態形成および活性を評価するための方法
US7147839B2 (en) Methods for evaluating tissue morphogenesis and activity
US20040176292A1 (en) Methods and compositions for enhancing cognitive function using morphogenic proteins
JP5075877B2 (ja) Ｏｐ／ｂｍｐモルフォゲンおよびｇｄｎｆ／ｎｇｆ神経栄養因子の相乗作用効果
D'alessandro et al. Bone morphogenetic proteins induce differentiation in astrocyte lineage cells
AU1122099A (en) Enhancement of morphogen activity
US6429196B1 (en) Treatment of balance impairments
Rodland et al. Cellular mechanisms of TGF-β action
Koh Ciliary neurotrophic factor released by corneal endothelium surviving oxidative stress ex vivo
WO1991014443A1 (en) A method for regulating neuron development and maintenance
Janiga et al. Differential effects of the trophic factors BDNF, NT‐4, GDNF, and IGF‐I on the isthmo‐optic nucleus in chick embryos
US20070066525A1 (en) Compositions and therapeutic methods using morphogenic proteins
EP0917469A1 (de) Verfahren zur induzierung der knochenbildung
JP2001507354A (ja) 局所的モルフォゲンまたは形態形成処理された筋形成前駆体細胞による哺乳動物心筋層の処置
AU635412B2 (en) A method for regulating neuron development and maintenance
WO2000066620A2 (en) Morphogen-induced enhancement of fertility

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: CURIS, INC.

Free format text: THE FORMER OWNER WAS: CREATIVE BIOMOLECULES, INC.

MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted